Science
Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19 – EurekAlert
This randomized clinical trial compares the effects of three doses of bamlanivimab monotherapy (700 vs 2,800 vs 7,000 mg) vs combination bamlanivimab and etesevimab…
What The Study Did: This randomized clinical trial compares the effects of three doses of bamlanivimab monotherapy (700 vs 2,800 vs 7,000 mg) vs combination bamlanivimab and etesevimab vs placebo on change in day 11 severe acute respiratory syndrome coronavirus 2 viral load in patients with mild to moderate COVID-19.
Authors: Daniel M. Skovronsky, M.D., Ph.D., of Eli Lilly and Company in Indianapolis, is the corresponding author.
To access the embargoed study: Visit our For The Media website at…
-
Noosa News24 hours agoSix to Try: Cafes in Brisbane Shaking Things Up
-
Noosa News23 hours agoQueensland government makes three-year 8 per cent pay rise offer to state’s school teachers
-
General23 hours agoLittle Zak’s Academy closes centre in Doonside after childcare workers charged
-
Noosa News21 hours agoThe story behind the historic Highgate Hill Queenslander destroyed by Brisbane storm